Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity ...Middle East

Drug firm Zydus Cadila said it has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market

Hence then, the article about zydus cadila gets usfda nod for arthritis drug with 180 days exclusivity was published today ( Monday 23/08/2021 - 12:00 PM ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity )

Also on site :

• How the Iran War Could Trigger a Global Credit Crunch
• FileCloud Achieves FedRAMP High Authorization, Enabling Secure Content Collaboration for Federal Agencies Handling Sensitive Data
• Chinese Oil Giants Return to Russian Crude After U.S. Sanctions Waiver